Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Motor Imagery Reaction Time in Individuals With Paraplegic Spinal Cord Injury

NCT07549087 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-04-20
Last updated
2026-04-23

Condition(s) studied

Spinal Cord Injuries

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

Individuals aged 18-65 years who have been clinically diagnosed with spinal cord injury and have developed paraplegia will be included in the study. Demographic and clinical data of the participants, including age, sex, height, weight, etiology of injury, level of injury, duration of injury, and comorbidities, will be recorded. In addition, disease-specific characteristics such as ambulation status, wheelchair use, presence of incontinence, and presence and severity of pain will be assessed. For the healthy control group, demographic data including age, sex, height, weight, and comorbidities will be recorded.

Motor imagery performance of the participants will be evaluated using a computer-based left/right judgment task. In this context, both upper extremity (hand) and lower extremity (foot) images will be used to record reaction time (motor imagery reaction time) and accuracy rate. All tests will be performed under standardized conditions, in a seated position, and using the same device.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Aged between 18 and 65 years * Clinically diagnosed with spinal cord injury * Presence of paraplegia * Injury duration of at least 3 months * Medically stable condition * Ability to understand and follow study instructions * Ability to complete the computer-based left/right judgment task * Willingness to participate and provide written informed consent * For the healthy control group: age- and sex-compatible individuals without a history of neurological or major musculoskeletal disease, willing to participate and provide written informed consent Exclusion Criteria: * Tetraplegia * History of other neurological disorders that may affect motor imagery performance * Severe cognitive impairment or communication problems preventing proper participation * Severe visual impairment uncorrected by glasses or lenses * Upper or lower extremity musculoskeletal disorders, deformities, or recent injuries that may affect task performance * Severe psychiatric disorder * Uncontrolled pain or acute medical condition at the time of assessment * Current participation in another interventional clinical study

Primary outcome measure(s)

  • Motor Imagery Reaction Time - Upper Extremity — Baseline
    Reaction time (in milliseconds) required to correctly identify left or right hand images in a computer-based motor imagery task. Longer reaction times indicate impaired motor imagery processing.
  • Motor Imagery Reaction Time - Lower Extremity — Baseline
    Reaction time (in milliseconds) required to correctly identify left or right foot images. Higher values indicate slower motor imagery performance.

Trial sites (1)

FacilityCityRegionStatus
Istanbul Physical Medicine and Rehabilitation Trainig and Research Hospital Istanbul Bahcelievler
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07549087 on ClinicalTrials.gov ↗ ← All trials in Turkey